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In 2003, South Africa’s National Department of Health (DoH) initiated the roll 
out of antiretroviral therapy (ART) for HIV positive individuals in the public health 
sector.  Based on World Health Organization (WHO) guidelines, South Africa’s ART 
programme provides a first line regimen based on a backbone of two nucleoside 
reverse transcriptase enzyme inhibitors (NRTI) with one non-nucleoside reverse 
transcriptase inhibitor (NNRTI) while the second line regimen is based on a 
protease inhibitor (PI) with two NRTIs.  Similar to many developing countries, South 
Africa’s NRTI backbone in the first line treatment regimen is stavudine (d4T) 
combined with lamivudine (3TC), and the NNRTI which is either efavirenz (EFV) or 
nevirapine (NVP).  In some cases, stavudine is replaced with the NRTI zidovudine 
(AZT) in the first line regimen.  Both d4T and AZT have been recognized to 
contribute to drug related toxicities or side effects, particularly lactic acidosis, 
lypodystrophy, peripheral neuropathy, and anaemia.  However, developing country 
governments have been limited to these NRTI choices due to the higher cost of 
alternative treatment options.   
There is compelling logic that the life long commitment of ART can be made 
more tolerable, and that adherence among patients and the success of a public 
sector ART programme can be increased through the provision of ART regimens 
with the fewest side effects.  In addition, the costs and complications associated 
with treating and managing adverse events associated with d4T and AZT create 
further burden on the public health sector.  By providing tenofovir as an alternative 
to d4T and AZT in first line ART therapy, the South African government would 
increase the chance of successful ART therapy for patients and the long-term 
success of the national ART programme.   
This cost effectiveness analysis will compare the currently available first line 
ART options (the status quo) to two alternative options in order to assess the cost-
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Chapter 1: Introduction 
 In 2003, South Africa’s National Department of Health (DoH) initiated the roll 
out of antiretroviral therapy (ART) for HIV positive individuals in the public health 
sector.  Based on World Health Organization (WHO) guidelines, South Africa’s ART 
programme provides a first line regimen based on a backbone of two nucleoside 
reverse transcriptase enzyme inhibitors (NRTI) with one non-nucleoside reverse 
transcriptase inhibitor (NNRTI) while the second line regimen is based on a 
protease inhibitor (PI) with two NRTIs.  Similar to many developing countries, South 
Africa’s NRTI backbone in the first line treatment regimen is stavudine (d4T) 
combined with lamivudine (3TC), and the NNRTI which is either efavirenz (EFV) or 
nevirapine (NVP).  In some cases, stavudine is replaced with the NRTI zidovudine 
(AZT) in the first line regimen.  Both d4T and AZT have been recognized to 
contribute to drug related toxicities or side effects, particularly lactic acidosis, 
lypodystrophy, peripheral neuropathy, and anaemia.  However, developing country 
governments have been limited to these NRTI choices due to the higher cost of 
alternative treatment options.   
 Patients experiencing severe d4T and AZT adverse events have limited 
ART options.  Depending on the severity of the adverse event, patients may be 
required to temporarily discontinue ART until the condition normalizes.  The 
monitoring and treating of these adverse events has serious cost implications for 
the public health sector.  When patients resume ART, often their only treatment 
option is the PI based second line regimen.  This, of course, limits future ART 
treatment options for the patient as, at present, no other treatment regimens are 
available in South Africa.  In addition to the patient experiencing severe adverse 
events requiring a change of treatment regimen, many of the unpleasant side 
effects of d4T and AZT may also contribute to non-adherence and defaulting of 
ART among patients.   
 In more affluent countries, the first line ART therapy of choice has moved 
from d4T and AZT based regimens, to a once daily Tenofovir DF (TDF) based 
regimen.  While the cost of tenofovir is significantly higher than d4T and AZT, 
tenofovir has been shown to have far fewer side effects and to have no association 
with lactic acidosis, lypodystrophy, peripheral neuropathy, or anaemia.  At present, 











available to only a very limited number of South African public sector patients 
through a compassionate programme of the manufacturer, Gilead Pharmaceuticals.   
 There is compelling logic that the life long commitment of ART can be made 
more tolerable, and that adherence among patients and the success of a public 
sector ART programme can be increased through the provision of ART regimens 
with the fewest side effects.  In addition, the costs and complications associated 
with treating and managing adverse events associated with d4T and AZT create 
further burden on the public health sector.  By providing tenofovir as an alternative 
to d4T and AZT in first line ART therapy, the South African government would 
increase the chance of successful ART therapy for patients and the long-term 
success of the national ART programme.   
 This study will compare the currently available first line ART options (the 
status quo) to two alternative options in order to assess the cost-effectiveness of 
the provision of tenofovir in place of d4T/AZT.  Option one is the provision of 
tenofovir for patients after the development of side effects.  Option two is the 
substitution of d4T/AZT for tenofovir in all patients with predisposing factors for the 











Chapter 2: Literature Review 
As this study deals with clinical management of patients on ART, this 
literature review will cover both clinical aspects of ART as well as technical aspects 
of cost-effectiveness studies.  The first three sections provide background on d4t, 
AZT, and TDF toxicity.  Sections 4 through 6 provide information on comparisons 
between d4T and TDF, AZT and TDF, and TDF only.  The final section provides 
information on cost-effectiveness studies including health economics, economic 
evaluation, and cost-effectiveness analysis.      
1. D4T Toxicity 
 Despite its effectiveness and affordability, d4T is no longer used in most 
affluent countries because of the numerous associated side effects.  The most 
prevalent of these side effects are peripheral neuropathy, hyperlactataemia and 
lactic acidosis, lipodystrophy, hepatoxicity, pancreatitis, and hepatosteatosis.   
 In a study conducted in Khayelitsha, South Africa, 20.8% of patients started 
on d4T based ART were switched off d4T by year 3.  Categorised by adverse 
event, 4.7% of patients switched due to symptomatic hyperlactataemia, 9,0% due to 
lipodystrophy, and 6,2% due to peripheral neuropathy (Boulle, et al., 2007).  The 
association of d4T with hyperlactataemia and lactic acidosis is particularly important 
due to the high mortality rate of 30-60% associated with these effects(Aid for Aids, 
2007).  Even in cases of less severe lactic acidosis, patients are permanently 
restricted from taking d4T.   
 In another study, 63% of patients on a d4T based regimen had signs of 
lipodystrophy by 14 months of treatment (McComsey, et al., 2004).  Lipodystrophic 
changes include the loss of fat from face and limbs with an increase of fat on the 
torso.  ART side effects that lead to physical disfigurement (lipodystrophy), physical 
discomfort (peripheral neuropathy), and severe toxicities (hyperlactataemia and 
lactic acidosis) may discourage patients from taking their ART. 
 Table A below details the major side effects of d4T, their symptoms, and 












Table A: Side effects of d4T 






• Abdominal pain 
• Rapid weight loss (5kg in 3 
months) 
• Fatigue (Kimani, et al., 
2006) 
• Shortness of breath 
(Mwebaze, et al., 2006) 
• Bloating (Lonergan, et al., 
2004) 
• Diarrhoea 
• Weight gain of  6kg in first 
3 months ART 
• Weight loss  3kg in last 3 
months prior to diagnosis 
• Concurrent PNP 
• 6-14 months on ART 
treatment (Osler, et al., 
2007) 
• Peripheral oedema 
• Peripheral neuropathy 
• Myalgia 
• Unexplained tachypnoea 
• Female gender 
• Baseline weight >60kg 
• Weight >75kg 
• Low CD4 
• High WHO stage 
• Muscle cramps 
• High BMI (mean 27) 
(Mohapi, et al., 2006) 
• Chronic renal failure 
• Pregnancy (National 
Department of Health 
South Africa, 2004) 
• Older age 
Lipodystrophy • Recent weight loss 
• Fat loss in arms, legs, 
buttocks, face 
• Fat gain in chest 
• Female gender 
• Baseline weight >75kg 
• >6months ART (Van 
Griensven, et al., 
2006) 
• Longer HIV 
• Advanced HIV (low 
CD4) 
• More NRTI experience 
• Older age 






• Greater age 
•  Higher WHO stage 
(weak associations) 
• CD4 <200 
• Female gender 












2. AZT Toxicity  
The side effect profile of AZT is less severe than d4T, however, a significant 
number of patients are affected by these side effects, influencing their ART options.  
Similar to d4T, AZT is associated with pancreatitis and hepatosteatosis.  The most 
common side effects of AZT are anaemia and neutropenia.  In the Khayelitsha 
study mentioned above, 7.8% of individuals switched from AZT by 3 years of 
treatment due to anaemia or neutropenia1.  In cases where patients are already 
restricted from d4T, the only present option in the public sector is a Kaletra (PI) 
based regimen.  As Kaletra is the backbone of South Africa’s public sector second 
line regimen, placing patients on a first line Kaletra regimen effectively eliminates 
second line treatment options.  If patients fail their Kaletra first line option, there is 
no further ART treatment available to them.     
Table B below details the major side effects of AZT, symptoms, and 
predisposing factors.   
Table B: Side effects of AZT 
Side Effect Symptoms Predisposing Factors 
Anaemia • weakness 
• fatigue 
• Baseline CD4 <50 
• older age 
• higher WHO stage 
Neutropenia • fevers 
• infections 
• Baseline CD4 <50 
• older age 
• higher WHO stage 
3. Tenofovir toxicity 
 With a longer half life than other NRTIs, tenofovir has the convenient benefit 
of once daily dosing, as opposed to D4T and AZT that require twice daily dosing.  
Combined with 3TC, tenofovir can be taken once a day, with or without food.  The 
simplicity of dosing and few side effects makes tenofovir a popular ART choice in 











 Primary concerns about tenofovir relate to nephrotoxicity1 and reductions in 
bone mineral density.  Tenofovir’s association with decreased bone density brings 
into question its suitability for use in children and pregnant women.  Animal studies 
with high-level doses (up to 14 times that given to humans) of tenofovir have not 
shown links to birth defects.  Long-term studies on monkeys have indicated the 
presence of biomarkers for defects in both mothers and foetuses.  In contrast to 
other NRTIs, tenofovir does not cause lactic acidosis, pancreatitis, anaemia, or 
neuropathy.   
The primary side effect of concern for tenofovir is the drug’s impact on renal 
function as analysed through creatinine clearance and creatinine levels.  Although 
clinical trials have shown tenofovir to have an excellent renal safety profile, there 
have been cases of renal impairment in various cohort studies and trials.  In most 
cases, nephrotoxicity has occurred in patients with baseline abnormal renal 
function. 
 An analysis of a prospective study comparing tenofovir (n= 344) with an 
alternative NRTI (n=314), showed that there were statistically significant increases 
in creatinine levels and decreases in creatinine clearance (indicating a tendency 
towards poorer renal function) in tenofovir patients.  However, the changes in 
creatinine and creatinine clearance were not large enough in magnitude to motivate 
for a change in regimen, indicating an unclear clinical significance (Gallant, et al., 
2005).  Another study looking at the association between tenofovir and 
hypophosphatemia2 (often linked with renal dysfunction), noted that the incidence of 
hypophosphatemia was slightly elevated in the tenofovir group but was not 
statistically different from the non-tenofovir group (Buchacz, et al., 2006).   
 In contrast to these studies indicating the uncertainty of the extent of clinical 
side effects of tenofovir, other researchers have reported case descriptions of 
tenofovir associated renal dysfunction (Karras, et al., 2003), and cohort studies 
showing elevated creatinines or declining creatinine clearances.  One study, with 
mean patient duration on tenofovir of 2.2 years, reports a decline in creatinine 
clearance in 7% of patients (>30% decline) with predictors for tenofovir related renal 
dysfunction being concurrent diabetes, and tipranavir /ritonavir use.   A high CD4 
count was protective (Crum-Cianflone, et al., 2006).  A second study included 
patients that had been on tenofovir for a period of at least 1 month and showed an 
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 Toxic effect on the kidney 
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elevation in creatinine in 7.3% of patients with hypertension, diabetes, and 
cardiovascular disease as co-morbidities (Piontkowsky, et al., 2006).  A third study 
indicated that, after a year of treatment with tenofovir, 18.5% of patients developed 
abnormal renal function, associated only with a low baseline weight.  In this last 
study, no association was found with diabetes or CD4 count (Rocha, et al., 2006).  
All three studies looked only at patients on tenofovir (no comparator group).  Table 
C below summarizes the toxicity of d4T, AZT, and TDF.   
Table C: Summary of toxicity of d4T, AZT, and TDF 
ART Side effect 






TDF Renal impairment 
4. D4T VS Tenofovir 
 The primary research conducted into the safety and efficacy of tenofovir in 
comparison to d4T has been by the 903 Study Group, closely linked to the producer 
of the drug, Gilead Pharmaceuticals.  The 903 Study Group encompasses 602 
enrolled patients followed for a period from 9 June 2000 to 30 January 2004.  The 
Study Group participated in studies looking at the efficacy of tenofovir in 
comparison to d4T as well as the renal safety of tenofovir in comparison to d4T.   
Through the Study 903 group, tenofovir has been shown be equivalent to 
d4T in terms of impact on HIV viral load at 48 and 144 weeks on treatment.  In 
addition, tenofovir is also associated with better lipid profiles and less lipodystrophy 
(Gallant, et al., 2004).  
An area of concern with tenofovir is its effect on renal function.  A second  
Study based on the Study 903 group showed that tenofovir and d4T have similar 











renal function (Izzedine, et al., 2005).  In another Gilead Sciences associated study, 
an evaluation of haematopoietic toxicity showed tenofovir to have lower toxicity than 
all other NRTIs with the exception of 3TC (Cihlar, et al,., 2002).  
 A small case control study of 54 patients looked at the effect on lactate 
levels of switching from d4T to tenofovir.  After 3 months on tenofovir, the case 
group showed a significant decrease in hyperlactataemia and a trend towards lower 
cholesterol levels (Class, et al., 2004).  
5. AZT VS Tenofovir 
 In a noninferiority study conducted comparing a first line ART regimen of 
tenofovir and emtricitabine to AZT, 3TC, and EFV, the efficacy and tolerability of 
tenofovir was proven.  At 48 weeks, significantly more patients in the tenofovir 
group reached and maintained a viral load of less than 400 copies per millilitre, 
reached and maintained a viral load of less than 50 copies per millilitre, and had a 
greater increase in CD4 count.  In addition, more patients in the AZT group 
discontinued their ART due to adverse events.  Anaemia was the most common 
cause of stopping AZT treatment but no cases were present in the tenofovir group.  
While renal side effects are a commonly mentioned concern with tenofovir, both the 
AZT and tenofovir groups showed similar levels of renal safety (Gallant, et al., 
2006). 
6. Developing Country Tenofovir Trials 
 Despite its cost, tenofovir has been accessible in some developing countries 
through ART trials.  These trials have looked at the tolerability of tenofovir in limited 
resource contexts. 
 A trial in Thailand was conducted with 100 patients starting on d4T/ddi and 
changing to tenofovir and 174 naive patients started on tenofovir.  The trial 
indicates that the use of tenofovir is not associated with decreased renal function 
through a median follow up period of 19.6 weeks (patients initially started on d4T) 
and 12 weeks (patients started on tenofovir) (Gayet-Ageron, et al., 2006).  
 In rural Uganda, the AHF/Uganda Cares clinic conducted a retrospective  
observational study of 1000 patients started on a tenofovir based regimen and 1000 











for a minimum of 72 weeks.  The study observed that no incidences of renal failure 
had been observed in the tenofovir group, and that the number of patients changing 
regimens was much lower in the tenofovir group, indicating greater tolerability 
(Okongo, et al., 2006).  
7. Cost effectiveness   
7.1 Health economics 
Health economics studies the allocation of resources in the health care 
sector.  In the theory of perfect competition, the firm is assumed to be a price taker 
and supply and demand dictates the price of a good.  However, the perfect market 
assumes that the product is homogenous, consumers are rational, there are no 
externalities, no public goods, perfect information is available, and there are a large 
number of buyers and sellers to prevent influence of the market.  The health care 
market does not fulfil the definition of a perfect market.  In health care there is 
imperfect information, externalities, public goods, questions of consumer rationality, 
barriers to entry and exit to the market, risk and uncertainty, and economies of 
scale and monopolies.   
The theories of Welfare Economics seek to describe conditions where social 
welfare can be maximized through alternative allocations of a good.  As the health 
care market is not a perfect market, resource allocation and price determination 
cannot be left to demand and supply.  The application of this sort of reasoning in 
Health Economics has tended to take an extra-welfarist approach where the 
maximization of overall societal welfare or utility is replaced by the maximization of 
health or health-related utility. Thus in Health Economics, efficiency is often defined 
in terms of the maximization of health within the health care budget constraint.  
 Because of the limits of the health care market, in addition to the positive 
economics of judgements about efficiency, normative economics that takes into 
account value judgements based on ethical principals should be applied.  With this 
framework, equity should also play a significant role in decision making.  The health 
system should not seek to help only individuals, it should help the entire population 
that it serves.  While equity is subjective, frequently used definitions include equal 
health, the equal utilization of health services for those of equal need and the equal 











As more options for facilitating health care become available, greater 
awareness of scarcity in the market and the need for efficiency develop, and the 
influence of other governments and donors increases, methods for guiding resource 
allocation and efficiency are needed.  Within the health system market and the 
decision making combination of positive and normative economics, the economic 
evaluation of health care programmes assists in choosing between options based 
on their costs and their outcomes.   
7.2 Economic evaluation 
 All full economic evaluations compare at least two alternatives and evaluate 
both cost and outcomes for all alternatives.  Cost is the value of resources used to 
produce something while opportunity cost is the benefit sacrificed in using the 
resource in one programme rather than another programme.  Outcomes are 
generally measured in disease specific units or in generic measures.   
 Efficiency within economic evaluation can be defined as maximizing health 
gains with the resources available to health care.  There are several measures of 
efficiency with technical efficiency and allocative efficiency being the most 
prominent in health economics. 
Technical efficiency can be defined as the production of a given quantity of 
output with the minimum value of inputs.  This implies that greater technical 
efficiency is attained through using the cheapest method of production (Clewer and 
Perkins 1998).  Technical efficiency can be viewed as doing things the right way.     
Allocative efficiency on the other hand strives to achieve an overall 
maximization of the health of society.  The value of the output therefore cannot be 
improved (Clewer and Perkins 1998).  Along with efficiency in production, allocative 
efficiency also implies efficiency in distribution.  It answers the question of how 
resources should be allocated to achieve the desired outcome.  In other words, 
allocative efficiency can be seen as doing the right thing.  In the health care sector, 
the most efficient use of resources occurs when those most in need of health care 
and the highest capacity to benefit are those that receive it.   
If a system is technically inefficient, the inputs can be reallocated to gain 
greater outputs.  However, once the inputs are maximized in terms of outputs, the 
system reaches the point of Pareto-optimality where there is no scope for efficiency 











if a system is operating at full allocative efficiency, it implies that it has reached 
optimal technical efficiency. 
 In addition to efficiency, economic evaluation can be used to consider the 
issue of equity.  Horizontal equity looks at the proportion of those with a need who 
receive a service.  Those who have equal needs should receive equal levels of 
service.  Vertical equity looks at the extent to which people with unequal health 
needs should receive unequal levels of service.  In order to attain maximum equity, 
it is often necessary to compromise efficiency.   
7.3  Cost effectiveness analysis 
 Cost effectiveness analysis looks at technical efficiency and asks which of 
various alternatives for treating the same condition would maximize health gains 
within the budget allocated to that specific health care programme.  An analysis 
contrasts the costs and outcomes of one or more interventions.  Cost effectiveness 
studies can either compare existing programmes or potential programmes.  A 
comparison of potential programmes, often referred to as a threshold study, 
determines the potential cost of a programme and the level of outcomes necessary 
in order to meet standards of cost-effectiveness.  
 By using the added costs and health outcomes associated with alternative 
interventions, the cost effectiveness analysis calculates the incremental cost 
effectiveness ratio (ICER) of one intervention in relation to another.  Health 
outcomes can vary from intermediate outcomes such as viral load suppression in 
HIV positive individuals to longer term outcomes such as quality adjusted life years 
(QALYs) (Gold, et al., 1996).   
 The ICER is calculated by dividing the additional costs of an intervention by 
the additional outcomes.   In a few circumstances, a proposed intervention may be 
less costly and more effective than the status quo.  In these circumstances, the 
intervention should be the preferred solution.  However, in most cases, the 
alternative interventions are more effective but also more costly than the status quo.  
In these cases, it is not possible to comment on technical efficiency as any decision 
to implement the programme to the same quantity of patients would require 
additional resources. Evaluating whether or not this is the right thing to do would 
require an assessment of the opportunity cost of moving resources from their 











Chapter 3: Methodology  
1. Introduction 
This chapter provides a review of relevant methodological literature and 
describes the methods used to select and calculate costs and outcomes for 
alternative first line ARV regimens and to determine the cost effectiveness of these 
options.  The options considered are: the status quo use of d4T and AZT, the 
provision of tenofovir for patients after the development of side effects on d4T and 
AZT, and the substitution of d4T/AZT with tenofovir in all patients with predisposing 
factors for the development of specified side effects.   Table D below illustrates 
these treatment options. 
Table D: Treatment Options 









Arm 1: Status quo D4T or AZT D4T or AZT D4T, AZT, or 
Kaletra 
Arm 2: Change to 
TDF upon side effect
D4T or AZT D4T or AZT TDF 
Arm 3: All 
predisposing start on 
TDF 
D4T or AZT TDF TDF 
Included in the calculations are data on patient utilization of health care 
(including facilities, lab tests, and medicines), side effects of medicines, regimen 
changes due to side effects, extraordinary utilization of health care due to side 
effects, treatment failure, and clinical outcome (viral load suppression).  As most 
drug side effects manifest within the first 18 months of treatment, patient inclusion 
has been limited to the GF Jooste cohort that has accessed ARVs for a full 18-











Despite a continuous scale up of the ARV services, requiring a minimum of 18 
months of follow-up meant that this number of patients is limited to 440.  
Data on health care utilization, medicines accessed and related issues, as 
well as clinical outcome for this analysis have been gathered from GF Jooste 
Hospital, a public sector secondary level institution.  Unit costs of health care are 
derived from studies based at GF Jooste and Khayelitsha primary level clinics.  It is 
assumed that costs for primary, secondary, and inpatient care at these two sites 
reflect standard South African public health facility standards.   
2. Methodology for patient level analyses 
2.1 Study population and setting  
Patients included in this study reside in the GF Jooste Hospital catchment 
area.  This region includes the “Cape Flats” areas of Gugulethu, Mitchell’s Plain, 
Khayelitsha, Philippi, Nyanga, Manenberg, and Hanover Park.   These “townships” 
represent an intersection of “coloured” and black (predominately Xhosa) 
communities.  Living conditions in these townships vary from basic single-family 
homes to over-crowded “dorms” to dilapidated “shacks.”  Access to running water, 
toilets, and electricity is often limited.  Gang violence and drug addiction is 
particularly rife in the coloured areas and personal safety is often a concern across 
the entire area.   
Through the international organization Medicens Sans Frontiers, 
Khayeltisha saw the introduction of HIV care into three primary level community 
health centres (CHCs) in 2000; this service was expanded to include ART in 2001.  
However, the remaining sections of the GF Jooste catchement area were only able 
to access ARVs and HIV care in December of 2003 when the Hospital implemented 
its Infectious Diseases Clinic.  Despite GF Jooste’s position as a secondary level 
hospital, due to an absence of adequate primary clinic care, the Infections Diseases 
Unit (IDU) was created to provide basic primary level HIV care.  In August 2004, as 
the ARVs became available at primary level clinics within the GF Jooste 
catchement area, a specialist, secondary level infectious diseases clinic (the 
Infectious Diseases Referral Unit- IDR) was created.  This clinic serves as the up-
referral site for patients with HIV complications stemming from drug side effects, 
HIV malignancies, and opportunistic infections.  Patients from primary care centres 











officers with extensive experience with complex HIV cases manage referred cases 
until they are stable enough to be referred back to primary care.  Through the IDR, 
patients have access to regular specialist consultations and more sophisticated 
diagnostic tools than that available at primary centres.   
GF Jooste Hospital was chosen for this research as it was one of the 
earliest health facilities providing ARV treatment according to Government public 
sector guidelines.  As the primary secondary level hospital for the Cape Town Cape 
Flats area, it services a representative population of public health care facility users 
in this area.  In addition, comprehensive patient records documenting both primary 
level (IDU) and, where applicable, secondary level (IDR and inpatient) hospital 
utilization and outcome are available.     
2.2 Study Timeframe and Sample Selection 
This study was conducted through a retrospective patient record review of 
infectious disease unit patients at GF Jooste Hospital.  Data were collected 
between June and December 2008.  All naïve patients commencing HAART at GF 
Jooste’s IDU between December 2003 and June 2006 who did not transfer out 
before 18 months of treatment were included (584 patients).  Data were available 
for 440 of the 584 eligible patients.    
2.3 Scope of Costs 
The cost effectiveness study should be framed for the intended primary audience of 
the study.  The primary audience is determined to be the relevant decision makers 
and their areas of interest.  The perspective of the study determines which costs 
and effects to include and how they should be valued.  By defining the perspective 
of the study, the researcher can ensure that all relevant costs are included.  As this 
study is conducted from a provider’s perspective, variable and fixed costs of the 
health care system are included.   
The provision of ARV medicine through the public sector requires 
comprehensive medical care including medicines, laboratory tests, clinical 
investigations, a range of human resources and skills and other variable resources.  
It also requires long-term investments into the health sector to maintain quality of 
care within and outside HIV medicine.  Costs in this study and secondary sources 
cited therefore include both variable and fixed costs.  The variable costs include the 
goods, services including human resources, and inputs that change over the course 











include medicines, laboratory tests, and clinical investigations.  Fixed costs are 
costs that do not vary with output over the short run or with the quantity of patients 
seen.  These costs include, among others, buildings and furniture (Clewer and 
Perkins 1998).   
Costs are categorized into total, average, and marginal costs.  All of these 
categorizations relate costs to quantity.  The total cost is the sum of the variable 
and fixed costs to produce a quantity of output.  The average cost is the average 
cost per unit of output or the total cost divided by the quantity.  The marginal cost is 
the extra cost of producing one extra unit of output (Clewer and Perkins 1998).  The 
marginal cost is thus related to the slope of the total cost curve.  If the change in 
total cost is increasing rapidly in relation to greater outputs, the marginal cost will be 
high.  If the change in total cost is increasing slowly in relation to greater outputs, 
the marginal cost will be low.    
In economic evaluation, marginal cost is the appropriate cost statistic to use.  
However, in practice it is difficult to estimate the marginal cost, with the result that 
the average total cost is used as a proxy.  In cost effectiveness analysis, the 
incremental cost-effectiveness ratio (the change in costs related to the change in 
effectiveness) is used to aid decision-making (Clewer and Perkins 1998).     
Health care utilization and clinical outcomes were gathered through a 
retrospective patient record review of the GF Jooste IDU.  The costs of lab 
procedures and antiretrovirals were assumed to be in line with standard public 
sector tender costs.  The unit costs of services including the cost per primary care 
visit, the cost per IDR visit and the cost per inpatient day were taken from 
secondary cost analyses previously undertaken on the GF Jooste and Khayelitsha 
cohorts.  For primary level ART services, costs were taken from secondary cost 
analyses undertaken at three Khayelitsha CHCs and the TC Newman district 
hospital (Cleary, et al., 2006).  Secondary level HIV care costs were derived from a 
costing study at GF Jooste Hospital (Kevany, et al., forthcoming) and revised to 
represent the current status of the IDR and wards.  In some cases, these cost 
analyses only collected incremental costs (excluding capital and overheads) while 
others calculated full economic costs. Adjustments were therefore made to these 
estimates, again through the use of available secondary data. 
Secondary data sources used for costing in this study have included a 
scope of costs based on average total costs.  The costs included in these studies 











below indicates the categories of costs included in the Khayelitsha study that 
provided cost data for primary care visits and inpatient ward days (Cleary, et al., 
2006). 
Table E: Scope of costs included in analysis for Khayelitsha study    
Health care resources 
Patient-specific costs (prophylactic and curative medicines, imaging) 
 Clinical staff (medical officers and professional nurses) 
 Overheads (non-clinical staff, running costs) 
 Capital (equipment, furniture, vehicles, buildings) 
Other related resources 
Counselling and support groups 
 Nutritional support 
Data from a case study of GF Jooste Hospital’s IDR clinic was used to provide cost 
information for the IDR appointments.  Costs included patient-specific and medical 
staff costs but excluded capital and overheads (Kevany, et al., forthcoming).   
2.4 Health Care Utilization 
Health care services associated with GF Jooste HIV treatment have been 
categorized into IDU (primary care), IDR (secondary care), and in-patient stays 
(secondary care).  Data on health care utilization for D4T and AZT users were 
collected from hospital records as part of this study.   
Utilization of clinic visits was established from 440 patients for the follow up 
period of 18 months.  Patients referred to the IDR and wards were followed up 
through hospital folders.   
2.5 Measuring clinical outcomes 
As a retrospective study based on a cohort of patients to whom no 
questions were asked regarding change in lifestyle, health, mobility, self care, or 











quality adjusted life years (QALYs) for this patient group.  It is, however, accepted 
that a patient’s HIV viral load is a good indicator of whether ART treatment is 
successful (Lawn, et al., 2005; Calmy, et al., 2007).  The clinical outcome for this 
study has, therefore, been determined as viral load suppression on first line ART at 
18 months on ARV treatment.   
3. Data Collection 
GF Jooste patient registers provided a list of all patients commencing ART 
between December 2003 and June 2006.  Available patient folders and hospital 
records were pulled to provide patient notes for all appointment attendances.   A 
data collection tool was used to note patient baseline information, predisposing 
factor(s), ART regimen, adverse event(s), management of the adverse event(s), 
and the outcome of the event(s) for each patient.  Data for all appointments 
including appointment date, patient weight, ART regimen, labs and investigations 
performed, side effects present, and any outcomes such as change in regimen, loss 
to follow up, or death were captured for every patient.  In addition, the outcome 
measure for this cost- effectiveness study, undetectable viral load at 18 months on 
ART, was also captured.   
4. Cost and Outcome Analysis 
Utilising data collected from this study, patients have been analysed within 
several cohorts.  From these cohorts, the costs and outcomes attributable to each 
treatment arm have been determined.  The costs and outcomes of the status quo 
have been determined from the data for all 440 patients.  The costs and outcomes 
of the second arm (patients change to TDF based regimens upon developing side 
effects) were assessed by separating the 440 patients into two cohorts- those that 
develop side effects that require a change in ART regimen and those that do not.  
Costs and outcomes for the third arm (all patients with predisposing factors start on 
TDF) were assessed by separating the 440 patients into two cohorts- those with 
predisposing factors and those without, and costs and outcomes were then based 
on the former.  In addition, the patients that did not change regimen due to side 
effects and did not have predisposing factors were analysed as the fifth cohort.  












Total costs for each costing category have been assessed for all patients 
across all visits.  For each cohort, average costs per category per quarter and over 
18 months were calculated by dividing total cohort costs by the number of patients 
in the cohort at each time interval.  ART costs were calculated based on the 
number of patients on each regimen at each time interval.  Laboratory costs were 
calculated by dividing the total laboratory costs per quarter by the number of 
patients active per quarter.  Data sorting, cleaning, and analysis was performed 
using Microsoft EXCEL 2000.   
4.1 Accounting for uncertainty 
Uncertainty in economic evaluation occurs at numerous levels related to the 
data requirements of a study as well as the process of evaluation.  Briggs and 
colleagues identified four key sources of uncertainty as methodological 
disagreement, data requirements, extrapolation of observed results over time, and 
generalizability to other settings.  This paper will only suffer from methodological 
and generalizability uncertainty as there has been no extrapolation of data or 
sampling.   
Methodological uncertainty in economic evaluation focuses on the debate 
around a variety of techniques to measure and value health outcomes and costs as 
well as the decision as to which costs and benefits to include.  Because the results 
of cost effectiveness studies only have meaning in relation to the results of other 
cost effectiveness studies, a core set of methods allows for better comparison 
between evaluations.  Most ‘reference cases’ define a set of methods and 
outcomes of ‘cost per life year’ and ‘cost per QALY’.  Sensitivity analyses can also 
be useful in determining whether the results of a study would change with different 
methods (Briggs, et al., 2004).   
As the reference case is not applicable to this study, the only uncertainty in 
data that is relevant is the question of discounting.  Discounting addresses the 
preference of spending in the future rather than the present.  Studies must decide 
whether to discount and, if so, how much to discount.  This study follows patients 
for a total of 18 months.  As discounting is only implemented after a time period of 
one year, the effect of discounting would be minimal.   
The uncertainty of the data relevant to cost-effectiveness studies and the 
measurement of ICERs can be dealt with through confidence intervals.  However, 











confidence intervals.  Varying theories on calculating the confidence interval include 
Fieller’s theorem, bootstrapping, and the Monte Carlo simulation.  These methods 
are useful for ICERS that have significantly positive numerators and denominators 
(the intervention is more costly and more effective).  In cases where the ICER is not 
significantly large in either numerator, denominator, or both, added complications 
arise.  As the ICER tends towards zero, the uncertainty rises rapidly.  In these 
circumstances, the uncertainty of the ICER can be calculated through acceptability 
curves or the net-benefit framework.  The acceptability curve graphs the possible 
cost of the programme against the probability of the programme being cost-
effective.  For every cost, it therefore summarizes the evidence in favour of cost-
effectiveness as well as provides information for the confidence interval on cost-
effectiveness.  The net-benefit framework rearranges the decision rule for cost-
effectiveness analysis to create a linear expression.  This allows the net-benefit to 
be plotted as a function of the cost.  The net –benefit curve crosses the horizontal 
axis at the point of estimated cost-effectiveness of the intervention.  The confidence 
curves cross the axis at the high and low ends of the confidence interval on cost-
effectiveness (Briggs, 2001). 
In cost-effectiveness studies where the cost and outcome data are 
synthesized from existing evidence (rather than directly observed), parameters are 
created to guide the model.  In these cases, there are known and unknown 
parameters.  Unknown parameters could be the probability of moving from one 
state to another over time and the costs and consequences of an intervention.  
Parameters are considered to be random variables and, in dealing with uncertainty, 
their values can be along the range of a determined distribution.  This distribution is 
selected to account for the uncertainty in the parameter rather than the variability in 
the population.  Acceptability curves can also be used to compare between multiple 
options.     
The generalizability of this study to other settings has been assessed by 
comparing reports of side effects to other published cohorts in low income countries 
(Okongo, et al., 2006; Gayet-Ageron, et al., 2006).  Inpatient and visit utilization 
data have been compared to the South African National Antiretroviral Treatment 
Guidelines 2004 for follow up of patients on ART.  Unit costs are taken from 
published secondary sources and official tender prices.  Outcomes have been 











Uncertainty in economic evaluation can be assessed using different types of 
sensitivity analysis.  These forms include simple sensitivity analysis, threshold 
analysis, and probabilistic sensitivity analysis.  
Simple sensitivity analysis involves varying one or more parameters one at 
a time within a plausible range while the other parameters remain at their set 
values.  This allows the investigator to determine the effect of variations in 
parameters on the result.  Multi way sensitivity analysis involves varying two or 
more parameters at the same time.  This is useful in analysing hypothetical 
scenarios that involve changes in several factors at once.  For example, patients in 
the study cohort have access to secondary and tertiary care for side effect 
management.  However, in other settings, these specialist institutions may not be 
available and palliative side effect management may not be available.  A scenario 
that reflects this situation would vary the costs of specialist care as well as loss to 
follow up rates.  Threshold analysis can also be used to determine at what 
parameter levels and combinations certain treatment options become cost neutral 
or cost saving.   
Probabilistic sensitivity analysis involves assigning each parameter a 
distribution of values.  Random values are selected from these distributions in a 
Monte Carlo simulation of the model to generate cost-effectiveness results.  This 
type of simulation captures variability in the parameter of interest rather than 
variability in the underlying population.          
In this thesis, a simple sensitivity analysis varying the percent of patients on 
TDF with viral load suppression has been conducted.  Furthermore, secondary 
source data on the TDF viral suppression was used to assess the outcomes 
associated with the TDF arm.  The change in outcome per arm and ICERs were 
calculated.  Threshold analyses were performed on the ICERs with secondary 
source data for TDF viral suppression.  These analyses determined prices at which 
the two alternative treatment arms become cost neutral and cost saving.    
5. Ethical Issues 
The University of Cape Town’s Research Ethics Committee approved the 
primary research on which this thesis is based.  The Infectious Diseases unit 
manager and the GF Jooste Hospital Ethics Committee approved access to GF 












This chapter has described the methodology that will be used in later 
chapters to calculate patient level costs and outcomes in alternative first line ART 
treatment regimens.  Uncertainty will be addressed using simple sensitivity analysis 
and threshold analysis.  Through data analysis, it will be possible to assess the 
health gains and costs associated with the four first line ART treatment options and 











Chapter 4: Results 
1. Introduction 
This chapter describes the total costs and outcomes of the three treatment 
options over an eighteen-month period.  Costs are set at September 2008 price 
levels and outcomes are presented as percent of patients on first line ART with viral 
suppression at 6, 12, and 18 months of ART therapy.
Costs include facility utilization (i.e. both primary and specialist outpatient 
care, and inpatient care) laboratory investigations, and ART drug costs.   
The original 440 patients were first divided into those who changed ART 
regimens due to side effects and those who did not have any change in regimen 
due to side effect.  Data from this analysis were used to calculate costs and 
outcomes for the second treatment arm (patients change to TDF once they develop 
side effects). 
The 440 patients were then analysed in two separate combinations.  
Patients were first divided into those with predisposing factors for side effects and 
those without predisposing factors.  Data from this analysis were used to calculate 
costs and outcomes for the third treatment arm (all patients with predisposing 
factors start on TDF).   
A third analysis was performed on the patients who did not have 
predisposing factors and did not develop side effects.  This last group was named 
‘remainder.’  Data from this group were used to calculate costs and outcomes for 
TDF. 
The ICERs for the three treatment arms and the threshold cost for each arm 
to be cost-neutral has been calculated.  
2. Unit costs 
Unit cost information for primary level infectious disease visits, capital cost 
data and unit cost information for inpatient days at GF Jooste Hospital were 
obtained from a secondary cost analysis previously undertaken on the Khayelitsha 











Referral visits was compiled from a 2005 costing of the IDR Unit (Kevany, et al., 
forthcoming).   
Lab costs were obtained from the National Health Laboratory Services 
(NHLS) State Price List 2008.  Table F shows the costs of common investigations 
performed with HIV patients.  Viral load, liver function, and lactate tests are the 
most costly investigations.  Viral load tests are performed for regular monitoring.  In 
cases where a patient is suspected of failing ART treatment or after treatment 
interruptions, additional viral load tests are done to ensure appropriate HIV 
management.  Patients on NVP have safety liver function tests done at two weeks 
on treatment.  Other than this safety test, liver function and lactate tests are done 
only for patients suspected of developing side effects to ART.  Management and 











Table F: Costs for laboratory investigations 
Laboratory Investigation Cost (Sept 2008 South African Rand) 
Full blood count 45.57 
Haemoglobin 14.18 
White Cell Count 14.18 
Differentials 24.99 
Platelets 16.80 

































ART costs were obtained from the ARV Depot price list for 2008.  At 
present, the standard first line ART drugs used in South Africa are stavudine (d4T), 
zidovudine (AZT), lamivudine (3TC), efavirenz (Efv), and nevirapine (NVP).  Four 
combinations of these drugs comprise South Africa’s basic triple-therapy first line 
ART regimens.  These first line regimens are d4T/3TC/Efv, d4T/3TC/NVP, 
AZT/3TC/Efv, and AZT/3TC/NVP.  The alternative first line regimen considered in 
this thesis is tenofovir (TDF) and Efv.  When a patient is no longer virally 
suppressed on a first line regimen, he/she is switched to second line ARV 
treatment.  The standard second line regimen in South Africa is Kaletra/AZT/ddI.  
However, a patient may also be put on dual therapy of Kaletra and Efv or mono 
therapy of Kaletra only.  Table G below indicates the cost per month of the ART 
regimens.  The cost of Kaletra makes second line ART management significantly 
more costly than first line treatment.   
Table G: Costs per ART regimen 
Regimen Cost per month (Sept 2008 SA Rand) 
D4T / 3TC/ Efv 171.93 
D4T / 3TC / NVP 83.53 
AZT / 3TC / Efv 128.34 
AZT / 3TC / NVP 216.74 
Kaletra / Efv 515.61 
Kaletra  394.07 
Kaletra / AZT/ddI (250mg if <60kg) 632.28 
TDF / Efv 288.31 
2.1 Adjustments to costs 
All data were adjusted to September 2008 price levels using the South African 
CPIX rate.  Data from Cleary were converted from US Dollars to South African 
Rand at the rate indicated in the study prior to adjusting for inflation.  Table H below 
indicates the cost of outpatient and inpatient visits.  The general cost function used 
to calculate these costs was; 
 Total cost= Costdrugs + Costlaboratory investigations +Costappointments + Costward day 
The rise in cost between standard primary appointments and referral 











from ART side effects and opportunistic infections.  As complications also lead to 
an increase in frequency of appointments, the cost of referral management is 
amplified.  Cases requiring inpatient stays further increase the cost of patient care.   
Table H: Costs per appointment type and ward day   
Appointment type Cost (Sept 2008 South African Rand) 
Primary level ID appointment 201.05 
GF Jooste IDR appointment 795.11 
GF Jooste Ward day 1230.97 
3. Outcome analysis 
The first treatment arm in this thesis has patients being initiated onto d4T or 
AZT based first line regimens.  Patients that develop side effects are managed 
according to the current status quo.  The 440 patients were therefore analysed as a 
whole to yield data for the costs and outcomes of this arm. 
The second treatment arm starts patients on d4T or AZT based regimens.  
Upon development of side effects requiring a change in regimen, patients are 
changed to TDF.  In order to obtain data to guide the costs and outcomes of this 
arm, the 440 patients were separated into two cohorts.  The first cohort includes all 
patients that develop side effects requiring a change in ART regimen (“side 
effects”).  The second cohort includes patients that do not develop side effects or 
develop side effects that do not require a change in ART regimen (“no side 
effects”).     
The third treatment arm in this thesis starts all patients with predisposing factors 
for ART side effects on a TDF based regimen.  All patients without predisposing 
factors would be started on the standard South African first line ART treatment.  
While there are several predisposing factors for d4T and AZT side effects, this 
thesis is concerned with side effects that lead to a change in ART regimen.  Factors 
associated with minor side effects such as peripheral neuropathy and anaemia 
have not been included.  The predisposing factors that are included are those that 
are associated with the development of lactic acidosis- weight at ART initiation 











In order to obtain data that guides the cost and outcome calculations for this 
second arm, the 440 patients were separated into two cohorts.  The first cohort 
included all patients with predisposing factors for side effects (“predisposing”).  The 
second cohort included all patients without predisposing factors for side effects 
(“non predispose”). Costs and outcomes are therefore calculated as a weighted 
average from these two groups.    
   Data for the costs and outcomes of TDF are not available in developing 
world settings.  This thesis uses a subset of the total patients to inform calculations 
of costs and outcomes for the patients that would be on TDF based regimens.  
These data are calculated from the cohort of patients that do not have predisposing 
factors and do not develop side effects (“remainder”).  Throughout this thesis, when 
a patient is placed on TDF, all cost and outcome data is sourced from this 
‘remainder’ cohort.  In arm 2, the costs and outcomes are attributed once patients 
change regimen due to side effects. In arm 3, these costs and outcomes are 
attributed to all patients in the “predisposing” cohort as they would be initiated on 
TDF therapy.  A detailed definition of each of these cohorts is presented below. 
1. TOTAL- All patients who were ART naïve and started ART treatment at GFJ 
between Dec 2003 and June 2006.  Patients who transferred out before 18 
months of treatment were excluded 
2. NO SIDE EFFECTS- Of the total patients, patients who did not change ART 
regimen due to side effects during their 18 months of treatment  
3. SIDE EFFECTS- Of the total patients, patients who changed ART regimen 
due to side effects during their 18 months of treatment 
4. NON PREDISPOSE-  Of the total patients, patients who did not have any of 
the predisposing factors  
5. PREDISPOSING- Of the total patients, patients who had predisposing 
factors 
6. REMAINDER-  Of the total patients, patients who did not have predisposing 
factors and did not develop side effects 
Table I below illustrates the gender composition of the various cohorts.  











one-third of those patients who develop side effects.  As female gender is a 
predisposing factor for lactic acidosis, all females are included in the predisposing 
cohort.   
Table I: Cohort Makeup 
Cohort Males Females Total 
Total 157 283 440
No Side Effect 117 189 306
Side Effect 40 94 134
No Predisposing 77 0 77
Predisposing 80 283 363
Remainder 61 0 61
 Table J demonstrates the breakdown of the total patient group.  A two-tailed 
chi- squared test shows that, between the ‘predisposing’ and ‘no predisposing’ 
cohorts, the proportion of patients developing side effects is not significantly 
different (P=0.0581).   
Table J: Cross Tabulation Illustrating Cohort Groups 
 Side Effect No Side Effect Total 
Predisposing  118 245 363 
No Predisposing 16 61 77 
Total 134 306 440 
3.1 Data Analysis 
Data were analysed in three monthly intervals.  Appointments that resulted 
in ward admissions were classified as IDR appointments.  Utilization data and side 
effect occurrence was noted per patient.  At each three monthly interval, patients 
were classified as either continuing on their ART treatment, changing ART 











           Patients in arm 1 (status quo) would flow through this basic decision tree 
until they reached an end stage or eighteen months of treatment. 
           Patients in arm 2 (patients change to a TDF based regimen upon developing 
side effects requiring a change) would all start on d4T or AZT regimens but would 
change to TDF regimens as soon as a change was needed.   
           Patients in arm 3 (predisposing patients start on TDF regimen) would also 
flow through this basic decision tree.  The primary difference would be that the 
starting regimen at time zero would be TDF based for all those with predisposing 
factors.  In addition, patients without predisposing factors requiring a change of 
regimen would ‘change regimen’ to a TDF based regimen as opposed to a d4T or 











Diagram A: Basic decision tree of model 
0 Months  3 Months   6 Months 3 month intervals 
  
3.2 Outcomes 
The effectiveness of ART therapy in controlling the HIV virus is monitored by 
testing the viral load of HIV in a patient’s blood.  In South Africa, viral load testing 
occurs at six monthly intervals.  A rise in viral load above the undetectable limit of 
400 copies per millilitre indicates that the patient’s ART regimen is no longer 
suppressing the HIV.  Viral load suppression is an indicator of whether ART is 
successful (Lawn, et al., 2005; Calmy, et al., 2007).  The percent of patients virally 
suppressed is the outcome measure for this thesis.   
Start of d4T, 
AZT, or TDF 
based regimen
Continue on 





Change regimen- No 
side effects 
Deceased 
Lost to follow up 
Stop regimen- Side 
effects 




Repeat of options  
for all branches 
except for patients 
that have been lost 
to follow up or 











For each cohort, the number of patients continuing on first line ART with 
viral suppression at six, twelve, and eighteen months was captured.  Viral load tests 
were allocated to the closest six-month interval.  Viral load suppression rates were 
calculated among those with viral load test.  As seen in Table I, viral load 
suppression rates are highest for the side effect and predisposing cohorts.  
However, the differences in outcome are not statistically significant.  The difference 
could be explained by more vigilant monitoring by medical officers, patient 
management by the GF Jooste IDR clinic, or self selection (patients with side 
effects that stay in care rather than become lost to follow up may be more 
adherent).  Table K below provides the number of patients with viral loads lower 
than detectable in relation to the total number of patients in the cohort, the percent 
of patients, and the confidence intervals.     
Table K: Outcomes by cohort  
Total No Side 
Effect 








































































3.3 Utilization of health services  
For all cohorts, the utilization that leads to the greatest cost burden is 
primary level appointments.  Across all time periods, the cost of medical 











in utilization in the first three months of ART care.  Chart A, below, shows the 
distribution of total costs per cohort by category.



































































The consistent factor that yields higher costs for those who develop side effects is 
laboratory investigations.  Chart B below illustrates the cost of laboratory 
investigations per cohort over six quarters.   


















































The ‘no side effect’ and ‘predisposing’ cohorts had the greatest proportion of 
patients started on AZT based regimens.  As medical officers are aware of the 
predisposing factors for d4T side effects, they try to start patients with predisposing 
factors on AZT.  This explains the greater proportion of patients on AZT in the 
‘predisposing cohort.’  As AZT has fewer side effects than d4T, patients on AZT are 
more likely to fall into the ‘no side effect’ cohort.  This discrepancy may have an 
impact on the outcomes of the cohorts.   As AZT is more expensive than d4T, this 
results in the ARV drug costs for the ‘no side effect’ cohort being greater than the 
costs for the ‘side effect’ cohort.  Despite the higher drug costs, the ‘no side effect’ 
cohort is less costly than the ‘side effect’ cohort in five of the six quarters.  
Excluding the cost of ART results in the ‘side effect’ cohort being more costly 
throughout the study period.  The breakdown of patients per regimen by cohort can 
be seen in Table J.   
Table L: Starting ART regimen per cohort 







d4T/3TC/Efv 296 201 95 64 232 51
d4T/3TC/NVP 76 49 27 2 74 2
AZT/3TC/NVP 31 29 2 0 31 0
AZT/3TC/Efv 27 23 4 8 19 6
Unknown d4T based 10 4 6 3 6 2
In order to conduct costing, regimens classified as ‘unknown d4T’ were 
allocated to d4T/3TC/Efv.  In Table J above, original data, with the unknown d4T 
regimens in the last row, is presented.  The second line regimens Kaletra plus two 
drug regimens were classified as Kaletra/ddI/Efv as this is the standard second line 
regimen.  Kaletra plus one drug regimens were classified as Kaletra/Efv.   
Over time, the total cost for patients who develop side effects increases over 
the other cohorts.  Chart C shows the trend of total cost per patient by cohort over 
six quarters.  It can be seen that the  ‘no side effect’ and ‘remainder’ cohorts have 
the lowest per patient cost by quarter six while the ‘side effect’ cohort has costs 















































The combined utilization of medical appointments, ART regimens, and 
laboratory investigations by cohort is documented in Table M below.  Appointment 
costs account for approximately two-thirds of the total costs for all cohorts in the 
first quarter.  Thereafter, they comprise approximately half of the total costs.  The 
spikes in laboratory investigation costs at quarters 2, 4, and 6 reflect regular 











 Table M: Utilization of health resources by cohort (cost per patient in SA Rands 
Sept 2008)  








All appointments 1362.46 1287.45 1545.17 1486.77 1336.09 1195.67
ART and laboratory costs 760.57 767.06 776.77 808.15 766.19 771.91
Total quarter 1 2123.03 2054.52 2321.93 2294.92 2102.28 1967.58
Quarter 2 
All appointments 695.22 695.69 727.24 591.49 716.97 572.80
ART and laboratory costs 848.80 887.74 858.28 819.68 880.65 815.43
Total quarter 2 1544.02 1583.43 1585.52 1411.17 1597.62 1388.23
Quarter 3 
All appointments 535.53 537.31 532.10 543.88 535.43.95 544.98
ART and laboratory costs 559.97 579.27 529.19 573.29 572.00 558.93
Total quarter 3 1095.51 1116.58 1061.29 1117.18 1107.43 1103.91
Quarter 4 
All appointments 647.57 554.35 755.58 758.42 624.22 547.25
ART and laboratory costs 836.48 810.62 885.47 769.21 850.65 756.93
Total quarter 4 1484.05 1364.98 1641.05 1527.63 1474.87 1304.18
Quarter 5 
All appointments 550.28 482.56 683.77 536.13 553.32 514.69
ART and laboratory costs 703.81 663.30 779.06 645.91 716.21 603.37
Total quarter 5 1254.09 1145.86 1462.83 1182.04 1269.53 1118.06
Quarter 6 
All appointments 490.94 461.04 547.04 531.83 482.26 514.45
ART and laboratory costs 865.83 823.52 944.99 835.66 876.10 805.48
Total quarter 6 1356.77 1284.56 1492.03 1367.49 1358.35 1319.93
18 month total 8857.47 8549.92 9564.66 8900.43 8910.10 8201.89
4. Treatment Arms Cost and Outcomes 
The cost, utilization and outcome data from the six cohorts provides the 











side effect profile of TDF is minimal, patients on TDF will have costs associated 
from the “remainder cohort.” 
4.1 Costs per arm 
4.1.1 Arm 1 Costs 
As arm one is the status quo, the total cost of arm one is the same as the total 
cohort cost. 
Arm 1 (current protocol) 
Total cost= Total cost of cohort “Total” 
Costs for arm 1 would therefore be the same as the ‘total’ cohort, R8857.47 per 
patient over 18 months.   
4.1.2 Arm 2 Costs 
In arm 2, patients that do not develop side effects requiring a change in regimen 
will have the costs of the “no side effects” cohort.  Patients that do develop side 
effects requiring a change in regimen will have costs from the “side effects” cohort 
until the regimen change.  After the regimen change, these patients will have the 
costs of the “remainder” cohort.  The cost of TDF is substituted for the remainder 
ART regimen costs.   
Arm 2 (patients who develop side effects switch to Tenofovir) 
Total cost=  from q1 to q6 ((Average cost per patient in NO SIDE 
EFFECTS * number of patients in NO SIDE EFFECTS) + (Average cost per 
patient in SIDE EFFECTS * number of patients in SIDE EFFECTS  who 
have not yet developed the side effect) + (cost TDF * number of patients 
who have developed side effects by beginning of quarter) + (average cost 
per patient in REMAINDER * number of patients who have developed side 
effects by beginning of quarter) 
The 306 patients that do not develop side effects have a cost of R8549.92 per 
patient over 18 months.   
Costs for patients that develop side effects are as follows: 
Twenty-four of 134 patients change regimen at the end of quarter 1.  These 
patients have the “remainder” cohort costs, excluding ART, for quarters 2 through 6 
of R3782.85 in addition to the quarter 1 “side effect” cohort costs of R2321.93.  The 











Twenty-six of 134 patients change regimen at the end of quarter 2.  These 
patients have “remainder” cohort costs, excluding ART, for quarters 3 through 6 of 
R2873.12 in addition to quarters 1 and 2 “side effect” cohort costs of R3907.45.  
The TDF regimen costs for quarters 3 through 6 totals R3459.72.   
Twenty-five of 134 patients change regimen at the end of quarter 3.  These 
patients have “remainder” cohort costs, excluding ART, for quarters 4 through 6 of 
R2247.00 in addition to quarters 1 through 3 “side effect” cohort costs of R4968.75.  
The TDF regimen costs for quarters 4 through 6 totals R2594.79.  
Thirty-six of 134 patients change regimen at the end of quarter 4.  These 
patients have “remainder” cohort costs, excluding ART, for quarters 5 and 6 of 
R1424.99 in addition to quarters 1 through 4 “side effect” cohort costs of R6609.80.  
The TDF regimen costs for quarters 5 and 6 totals R1729.86.  
  Sixteen of 134 patients change regimen at the end of quarter 5.  These 
patients have “remainder” cohort costs, excluding ART, for quarter 6 of R813.43 in 
addition to quarters 1 through 5 “side effect” cohort costs of R8072.63.  The TDF 
regimen costs for quarter 6 is R864.93.   
The 7 patients that change at the end of quarter 6 have “side effect” cohort 
costs for all quarters of R9564.66. 
The patient cost for those that develop side effects in arm 2 is therefore 
R9972.49 over 18 months.   
The weighted patient cost for arm 2 is R8983.16.  Table N below 
summarizes these costs per quarter.  Pre side effect quarter costs are in italics.  
Costs per quarter after side effect, excluding cost of TDF are in normal font.  Total 



















Q1 cost Q2 cost Q3 cost Q4 cost Q5 cost Q6 cost TDF costs
Total cost 
per patient  
Total (number of 
patients * cost 
per patient) 
No 
change 306 2054.52 1583.43 1116.58 1364.98 1145.86 1284.56 0.00 8549.92
2616275.52
Q1 24 2321.93 909.72 626.12 822.01 611.56 813.43 4324.65 10429.43 250306.3
Q2 26 2321.93 1585.52 626.12 822.01 611.56 813.43 3459.72 10240.29 266247.6
Q3 25 2321.93 1585.52 1061.29 822.01 611.56 813.43 2594.79 9810.54 245263.4
Q4 36 2321.93 1585.52 1061.29 1641.05 611.56 813.43 1729.86 9764.65 351527.3
Q5 16 2321.93 1585.52 1061.29 1641.05 1462.83 813.43 864.93 9750.99 156015.8
Q6 7 2321.93 1585.52 1061.29 1641.05 1462.83 1492.03 0.00 9564.66 66952.63
      
Arm 2 patient 
cost  9972.49
4.1.3 Arm 3 Costs 
In arm 3, the patients without predisposing factors will have the costs of the 
“non predispose” cohort.  Patients with predisposing factors will be started on TDF 
and will have the costs from the “remainder” cohort.  The cost of TDF is substituted 
for the ART cost in the remainder cohort.   
Arm 3 (patients with predisposing factors start on Tenofovir) 
Total cost=  from q1 to q6 ((Average cost per patient in NON 
PREDISPOSE * number of patients in NON PREDISPOSE) + ((cost TDF * 
number of patients in PREDISPOSE) + (Average cost per patient in 
REMAINDER * number of patients in PREDISPOSE)) 
The 77 patients without predisposing factors have a cost of R8900.43 per patient 











The remaining 363 patients with predisposing factors have a TDF ART 
regimen cost of R864.93 per quarter or R5189.58 per 18 months.   The other costs 
from the “remainder” cohort total R5256.19 per 18 months.  The total cost for 
patients with predisposing factors would then be R10445.77.   
The weighted patient cost for the cohort would be ((77/440) * R8900.43) + 
((363/440) * R10445.77) or R10175.34 per patient over 18 months.   
4.2 Outcomes per arm 
4.2.1  Arm 1 outcomes
As seen in Table G above, of patients in the cohort at the beginning of each 
six-month interval, 93.4% (0-6 months), 90.7% (6-12 months), and 86.3% (12-18 
months) of patients were on first line ART and had undetectable viral loads. 
4.2.2  Arm 2 outcomes 
The 306 patients that do not develop side effects resulting in a change of 
ART regimen would have the outcomes of the ‘no side effects’ cohort.  The 
outcomes would therefore be 93.1%, 89.1%, and 86.1% of patients on first line ART 
with undetectable viral loads at 6, 12, and 18 months.   
The 134 patients that develop side effects and change regimen would have 
outcomes related to the ‘side effects’ cohort before they change regimen and the 
outcomes of the ‘remainder cohort’ after their change of regimen.  Patients that 
develop side effects and change regimen more than once are assigned to change 
to TDF regimens on the first change of regimen.   
According to Table N above, 24 patients changed ART regimen in the first 
quarter, 26 in the second, 25 in the third, 36 in the fourth, 16 in the fifth, and 7 in the 
last quarter.  The outcomes for these patients would be calculated as shown in 











Table O: Arm 2- Outcome allocation  






Quarter 1 Side effect cohort  Remainder cohort Remainder cohort 
Quarter 2 Side effect cohort  Remainder cohort Remainder cohort 
Quarter 3 Side effect cohort  Side effect cohort  Remainder cohort 
Quarter 4 Side effect cohort  Side effect cohort  Remainder cohort 
Quarter 5 Side effect cohort  Side effect cohort  Side effect cohort  
Quarter6 Side effect cohort  Side effect cohort  Side effect cohort  
No Change Side effect cohort  Side effect cohort  Side effect cohort  
The six-month outcome for this group of arm 2 would therefore be the same 
as that for the side effect cohort or 93.8% of patients on first line ART with 
undetectable viral loads.  At twelve months the 50 patients that switch regimens in 
quarter one or two will have an outcome of 88.9% while 84 will have an outcome of 
93.7%.  At eighteen months, the 111 patients that change regimen in quarters one 
through four will have an outcome of 86.1% while the remaining 23 patients will 
have an outcome of 86.46%.   
This yields outcomes of 93.3%, 90.0%, and 86.2% of patients on first line 











Table P: Outcome Summary- Viral load suppression for Arm 2 




6 month viral load 
suppression 
12 month viral load 
suppression 
18 month viral load 
suppression 
no side effects 306 93.1 89.1 86.1
side effects q1 and q2 50 93.8 88.9 86.1
side effects q3 and q4 61 93.8 93.7 86.1
side effects q5 and q6 23 93.8 93.7 86.5
Total weighted outcome 93.3 90.0 86.2
4.2.3  Arm 3 outcomes 
The 363 patients with predisposing factors would be started on TDF based 
regimens and are assumed to have outcomes similar to the ‘remainder’ cohort.  At 
six, twelve, and eighteen months, this group would therefore have 90.2%, 88.9%, 
and 86.1% of its patients on first line ART with undetectable viral loads.   
The remaining 77 patients would have the outcomes of the ‘non 
predisposing’ cohort with 92.5%, 87.5%, and 84.8% of the patients on first line ART 
with undetectable viral loads.   
Proportionally, the outcomes would be ((363/440) * outcomeremainder) + 
((77/440) * outcomenon predispose) for each six- monthly interval.  This yields outcomes 
of 93.4%, 90.8%, and 86.3% for the arm.  These outcomes are summarized in 











Table Q: Outcome Summary- Viral Load Suppression for Arm 3   
Arm 3 Outcome Summary    
patient group number of patients
6 month viral load 
suppression 
12 month viral load 
suppression 
18 month viral load 
suppression 
predispose 363 90.24 88.9 86.1
non predispose 77 92.45 87.50 84.78
total weighted outcome 90.63 88.65 85.88
4.3 Results of Cost Effectiveness Analysis 
Table R below summarizes costs and outcomes for the three arms.  The 
costs per patient are highest in arm 3 and lowest in arm 1.  The outcomes are best 
in arm 1 and worst in arm 3.  However, the outcomes are not statistically significant 











Table R: Summary of costs and outcomes per arm 

















Arm 1 (status 
quo) 






Arm 2 (change 










Arm 3 (all with 
predisposing 
factors start on 
TDF) 






As there is no significant difference in outcome, it is not possible to calculate 
an ICER for the alternative treatment arms.  The status quo is both less costly and 
equally effective as the alternatives.  These results will be further unpacked using 
sensitivity analysis.   
4.4 Threshold Prices for TDF 
          Arm 2 would become cost neutral at a TDF price of R240.68 per month.  This 
is 83.5% of the R288.31 price used in this study.  Arm 3 would become cost neutral 
at a TDF price of R199.40 per month.  This is 69.2% of the price used in this study.     
4.5 Simple Sensitivity Analysis 
Given the lack of data on the effectiveness of TDF in viral suppression, 
simple sensitivity analyses were conducted exploring a range of rates of viral load 
suppression among patients on TDF, using data from published prospective cohort 











efavirenz with patients on stavudine, lamivudine, and efavirenz (Study 903 Group).  
The second compared patients on a regimen of TDF, emtricitabine, and efavirenz to 
patients on fixed-dose zidovudine, lamivudine, and efavirenz (Study 934 Group).  
While most of the patients in this study are started on a d4T-based regimen, 
comparing outcomes to AZT regimens is also useful.   
The Study 903 Group comparing a TDF regimen to a d4T regimen had viral 
load suppression rates for the cohorts at 12 and 24 months.  The 24 month data 
were used in 18 month sensitivity analysis in this study.  At 12 months, 239 of 299 
patients in the TDF cohort were viralogically suppressed with viral loads under 400 
copies per millilitre (79.9 percent) while 253 of 301 patients in the d4T cohort were 
suppressed (84.1 percent).  Those there was a significant difference in viral 
suppression at 400 copies per millilitre, TDF and d4T were shown to be equally 
effective in suppressing HIV viral load at the 50 copies per millilitre level (TDF% vs 
d4T%).  At 24 months, 226 of 299 patients in the TDF cohort were viralogically 
suppressed (75.6%) while 214 of 301 patients in the d4T cohort were suppressed 
(71.1 percent) (Gallant, et al., 2004).  
The Study 934 Group comparing a TDF regimen to an AZT regimen had 
viral load suppression rates for the cohorts at the 12 month time interval only.  At 
12-months, 206 of the 244 patients in the TDF cohort had viral load levels of less 
than 400 copies per millilitre (84 percent) while 177 of the 243 patients on the AZT 
cohort were viralogically suppressed (73 percent) (Gallant, et al., 2006).   
The rates of viral suppression for the TDF cohorts and the AZT and d4T 
cohorts from Study 903 and 934 were substituted for the outcomes calculated in 
this study to yield these sensitivity analyses.   A summary of substitutions is shown 










Table S: Summary of Sensitivity Analysis Outcome Substitutions 
 6 Month Viral Load 
suppression 
percentage 
12 Month Viral Load 
suppression 
percentage 
18 Month Viral Load 
suppression 
percentage 
 Patients on 
 D4T/AZT TDF D4T/AZT TDF D4T/AZT TDF 
Study 
903 
NA NA 84.1% 79.9% 71.1% 75.6% 
Study 
934 
NA NA 73% 84% NA NA 
    
For sensitivity analysis with data from Study 903, outcomes for Arm 1 were 
calculated by substituting the d4T outcomes from Study 903 for data from this 
study.  As all patients in Arm 1 are on d4T, the percent virally suppressed would be 
84.1%.  Sensitivity analysis outcomes for Arm 2 were calculated in the same 
manner as in section 4.2, “Outcomes per Arm.”  Patients that developed side 
effects would be switched to TDF and therefore have the outcome of TDF patients 
from Study 903.  Patients that had not developed side effects would be on d4T or 
AZT and therefore would have the outcome of d4T patients from Study 903.  Table 
T below shows the distribution of outcome data in calculating the final outcomes for 











Table T: Arm 2 Outcome Calculation with Study 903 Data  




6 month VL 
suppression (%) 
12 month VL 
suppression (%) 
18 month VL 
suppression (%) 
no side effects 306 NA 84.1 71.1
side effects q1 and q2 50 NA 79.9 75.6
side effects q3 and q4 61 NA 84.1 75.6
side effects q5 and q6 23 NA 84.1 71.1
Total weighted outcome NA 83.6 72.2
 Sensitivity analysis with Study 903 data for Arm 3 was also calculated in the 
same manner as described in section 4.2, substituting the outcomes from Study 
903 for the data from this study.  Patients that are in the “predispose” cohort will be 
started on TDF and therefore will have data from the Study 903 TDF patient group.  
Patients in the “non predispose” cohort will be started on d4T or AZT and will have 
data from the Study 903 d4T patient group.  Table U below illustrates the assigned 
and weighted outcomes for Arm 3.      
Table U: Arm 3 Outcome Calculation with Study 903 Data 
Arm 3 Outcome Summary    
patient group number of patients
6 month VL 
suppression (%) 
12 month VL 
suppression (%) 
18 month VL 
suppression (%) 
predispose 363 NA 79.9 75.6
non predispose 77 NA 84.1 71.1
total weighted outcome NA 80.6 74.8
 Study 934 data were substituted in the same manner described above in 
order to calculate sensitivity analysis outcomes.  Tables V and W below illustrate 











Table V: Arm 2 Outcome Calculation with Study 934 Data 




6 month VL 
suppression (%) 
12 month VL 
suppression (%) 
18 month VL 
suppression (%) 
no side effects 306 NA 73 NA
side effects q1 and q2 50 NA 84 NA
side effects q3 and q4 61 NA 73 NA
side effects q5 and q6 23 NA 73 NA
Total weighted outcome NA 74 NA
Table W: Arm 3 Outcome Calculation with Study 934 Data 
Arm 3 Outcome Summary    
patient group number of patients
6 month VL 
suppression (%) 
12 month VL 
suppression (%) 
18 month VL 
suppression (%) 
predispose 363 NA 84 NA
non predispose 77 NA 73 NA
total weighted outcome NA 82 NA
Tables X and Y summarize the sensitivity analysis outcomes for all arms.  As rates 
of viral suppression were taken from the literature, the outcomes in the sensitivity 
analysis are different.  At 12 months, d4T had a greater number of patients with 
viral load below 400 copies per millilitre.  This results in a poorer outcome for 
patients on TDF in this sensitivity analysis.  The outcome of each arm decreases in 
proportion to the increase in patients on TDF as seen in Table X.  In contrast, in 
comparison to AZT, TDF has been shown to have greater efficacy.  This results in a 
higher viral load suppression rate for patients that would be on a TDF regimen as 
seen in Table Y.  As arm 3 has the greatest number of patients on TDF, the 











Table X: Sensitivity Analysis Outcome Summary (Using data from Study 903)
Option 
6 Month VL 
Suppression (%) 
12 Month VL 
Suppression (%)
18 Month VL 
Suppression (%)
Arm 1 NA 84.1 71.1 
Arm 2 (TDF upon SE) NA 83.6 72.2 
Arm 3 (TDF for all predisposing) NA 80.6 74.8 
Table Y: Sensitivity Analysis Outcome Summary (Using data from Study 934)
Option 
6 Month VL 
Suppression (%)
12 Month VL 
suppression (%) 
18 Month VL 
Suppression (%)
Arm 1 NA 73 NA 
Arm 2 (TDF upon SE) NA 74 NA 
Arm 3 (TDF for all predisposing) NA 82 NA 
The sensitivity analyses result in adjusted ICERs for each of the treatment 
arms.  These ICERS are indicated in Table Z.  Using data from Study 903, both 
arms 2 and 3 have better outcomes at 18 months than the status quo.  This yields 
ICERS of R114.26 per percent of patients virally suppressed gained in 18 months 
on arm 2 and R456.77 per percent viral load suppression gained on arm 3 over arm 
2.  In other words, in a cohort of 100 patients, for each additional patient virally 
suppressed, it would costs R114.26 on arm 2 over arm 1 and R456.77 on arm 3 











Table Z: Sensitivity Analysis ICERs with Study 903 data 
Cost of programme First line ART 
regimen 
alternatives 








Status quo (arm 1) 8857.47 71.1  
Change to TDF 
upon development 
of side effect 
requiring change 
(arm 2) 
8983.16 72.2 R114.26 per 
percent 
undetectable viral 
load gained over 
arm 1 
TDF start for all 
with predisposing 
factors (arm 3) 
10175.34 74.81 R456.77 per 
percent 
undetectable viral 
load gained over 
arm 2 
As Study 934 does not have 18 month viral load data, the ICER needs to be 
calculated with outcome data at the 12 month interval (costs remain over 18 
months).  This also results in both arm 2 and 3 having better outcomes at 12 
months than the status quo.  The ICERs at 12 months are R96.68 per percent of 
patients virally suppressed gained on arm 2 and R153.24 per percent viral load 
suppression gained on arm 3 over arm 2.  The results of sensitivity analysis are 











Table AA: Sensitivity Analysis ICERs with Study 934 data 
Cost of programme First line ART 
regimen 
alternatives 








Status quo (arm 1) 8857.47 73  
Change to TDF 
upon development 
of side effect 
requiring change 
(arm 2) 
8983.16 74.3 R96.68 per percent 
viral load gained 
over arm 1 
TDF start for all 
with predisposing 
factors (arm 3) 
10175.34 82.08 R153.24 per 
percent viral load 











Chapter 5: Discussion 
1. Introduction 
Resource poor, high HIV burden countries, are unlikely to have the human, 
infrastructural, or financial resources to treat all HIV positive individuals who are in 
need of ART.  It is therefore necessary to consider how to ration treatment for as 
long as demand exceeds supply (Rosen, et al., 2005).  Questions of distributive 
justice and how effective equitable ART care can be best delivered must be 
considered (Capron and Reis 2005; Egger, et al., 2005).  
While the developed world has access to numerous drugs, sophisticated 
laboratory tools, and greater financial resources, treatment models for the 
developing world need to rely on simplification and decentralization of treatment.  
One component of simplification is the choice of drug regimen.  The provision of a 
fixed-dose combination will facilitate adherence, optimising the chances of long-
term success for ART.  In addition, it will ease the pressure on supply chain 
management (Calmy, et al., 2004).   
One choice for the simplification of ART regimen is the switch to a TDF 
based regimen.  However, this switch involves increased expenditure on ART that 
is only partially offset by decreased management expenses.  Unless the budget can 
be increased, the greater costs of TDF regimens would equate to a less equitable 
HIV programme as fewer people would have access to ART. 
The benefits of TDF regimens to the patient include decreased pill burden 
and fewer side effects.  Patients in settings where resources are not as limited have 
elected to access TDF for these benefits.  The simplification of patient and health 
system management with a switch to TDF is also a significant consideration.  For 
these reasons, information reflecting on the cost-effectiveness and cost- neutral 
status of a TDF first line regimen are necessary.  If more beneficial health initiatives 
can be introduced without compromising the equity of the health system, steps 
should be taken towards implementation.   
This thesis has indicated that significant financial resources would need to 
be invested in order to implement a TDF based first line regimen in South Africa.  If 
500,000 new patients are in need of ART every year, implementing arm 2 would 











expenditure.  If arm 3 were to be implemented, it would cost R658,935,000 more 
than the status quo or an increase of 15% in expenditure.   
In addition, with available outcome data, the benefits in terms of viral load 
suppression are not significant.  However, quality of life and survival have not been 
considered in the outcomes.  These would offer a more complete picture of the 
impact of TDF on the patient.  The decrease in price of TDF to reach cost-neutrality 
in one intervention arm is not large.  Sensitivity analysis with viral load outcome 
data from studies in the developed world has yielded ICERs that could help to 
advise on future implementation.  The generalizability of this thesis to broader 
settings and the implications are discussed below.   
2. Generalizability 
GF Jooste hospital is an urban secondary level facility in the Western Cape.  
The resource limitations and conditions of rural facilities and health systems of 
other provinces may result in a difference in patient management capabilities, costs 
and outcomes.   
2.1 Utilization of the health care system 
The ARV Treatment Protocol for the Western Cape states that patients 
should be monitored by a medical officer at 4, 8, and 12 weeks on treatment.  
Thereafter, patients should be seen 3-monthly by medical officers and monthly by 
nurses (Provincial Administration Western Cape, 2004).  In comparison, utilization 
data from this study indicates that patients averaged 5.5 appointments in the first 3 
months and had appointments slightly more frequently than once monthly after the 
initial 3 months on ART (1.1 appointments per month).  All appointments involved 
medical officer consultations.  The greater utilization in this patient group leads to 
higher costs for general HIV management.  This would decrease the impact that 
side effect management, with increased utilization, would have on the overall cost.     
2.2 Rate of retention in care 
A review of studies in sub-Saharan Africa concluded that African ART 
programmes are retaining approximately 60% of their patients in the first two years 
of ART care.  Patients transferred to another ART site were considered to remain in 
care.  There was significant heterogeneity between the studies with the spectrum 











across the studies and impact on the survival rate of patients (Rosen, et al., 2007).  
In comparison, the cohort of patients in this study had a retention rate of 85% 
(374/440) at 18 months.   
2.3 Viral load suppression rates 
In a study of ART patients predominately residing in Cape Town’s urban 
township areas, 70.9% of on-treatment patients had HIV viral load levels below 400 
copies/ml at 12 months on ART (Orrell, et al., 2003).  A study of patients in 
Khayelitsha township had a viral load suppression rate of 75% at 18 months on 
treatment (Coetzee, et al., 2004).  While the study in Khayelitsha looked at patients 
in a public primary care setting, both studies were conducted on health services 
provided by NGO assisted programmes.  A third donor funded ART programme in 
rural South Africa had 83% of its on treatment patients with viral load lower than 
400 copies/ml at 12 months (Barth, et al., 2008).  This study had 86.3% of those 
with viral load tests virally suppressed at 18 months on ART.  The higher rate of 
viral suppression in the Jooste cohort could be explained by the presence of the 
IDR clinic, better monitoring of side effects, and lengthier and more thorough visits. 
3. Strengths and weaknesses/limitations 
In contrast to most cost analyses in South Africa, this study includes both 
outpatient and inpatient costs.  In addition to primary and secondary ward costs, 
secondary referral costs are also included.  Human resource costs comprise a 
significant portion of the secondary inpatient and referral service costs and result in 
significantly more expensive management.  As human resource constraints are one 
of the major restrictions in the public health system, a costing that reflects 
components of patient management at all levels is important for appropriate policy 
decisions.  In addition to improved outcomes, interventions should be considered in 
relation to the effective use of other scarce resources.  If TDF can reduce the need 
for clinical services, it may be a reasonable intervention to implement.   
In addition to representing 2 levels of patient care, GF Jooste Hospital is a 
standard public sector urban facility.  The resources and constraints that affect GF 
Jooste are valid for public facilities across South Africa.  While the IDR is unique to 
the hospital, it maintains a cost lower than that of inpatient care.  If it is to be 











stays, the cost of side effect management would increase.  The costing with the 
IDR could be seen as a best case scenario. 
 As patient data were only available in paper form, a considerable amount of 
time was spent on data collection.   Numerous data points were extracted from 
every patient visit.  In order to collect data on inpatient stays, hospital folders were 
located and reviewed.  These data allow for the inclusion of primary and secondary 
costs as well as all recorded laboratory investigations.   
Limitations in data availability on TDF interventions in the developing world 
results in a number of assumptions for incidence of side effects as well as 
outcomes.  However, due to the extensive data collection, the assumptions were 
kept to the lowest level possible.  Secondary data from the literature have been 
used primarily in sensitivity analysis on patient outcomes.   
Due to the high cost of TDF regimens, this study has looked at alternatives 
to the implementation of TDF as the full first line regimen.  It has instead 
investigated options that may best benefit patients and the health care system by 
targeting those in most need for TDF.  By suggesting alternative means of 
implementing TDF, this study provides information on the cost-effectiveness of 
practical means of implementation of TDF while minimizing inequity.   
During the period from which this study drew its patients, a prospective trial 
of an adherence support model was in operation at GF Jooste Hospital.  The trial, 
the DOT-HAART study, involved volunteer treatment supporters that provided direct 
observational support for ART patients.  It is possible that increased monitoring and 
selection biases were introduced through this trial and that the patient group does 
not reflect the standard public sector primary care patient cohort.  The majority of 
the patients in this study were in the DOT-HAART cohort.  However, this study 
looks at cohorts within the group in comparison to each other.  Therefore, the 
difference in outcomes between groups is not affected.   
           In addition, GF Jooste is a secondary care facility.  The primary level 
infectious diseases clinic was initiated in order to fulfil a need when primary level 
facilities were not available in the area.  The patient group has a larger geographic 
range than would be present in most primary clinics.  The patients may also have 
had clinical or other differences from average primary sector patients. 
As the primary level clinic is situated within the same facilities as the 











in hospital notes.  Because of this, only visits that resulted in inpatient admissions 
were allocated to IDR appointments.  This has lead to underestimation of IDR 
appointments and therefore a lower cost involved with complications on ART.    
Without access to computer based patient data and with limited time, the 
sample size of the study (440 patients) is small.  This has led to large confidence 
intervals. 
  Patient information was captured from patients initiating ART between 
December 2003 and June 2006.  Most of these patients completed 18 months of 
ART before the decision was made to reduce the recommended dosage of d4T.  
This reduction in dosage and increased awareness of early symptoms for lactic 
acidosis has reduced rates of hyperlactataemia and lactic acidosis.  This reduction 
would reduce the prevalence of d4T related side effects and therefore reduce the 
costs associated with management of d4T side effects.   
  Data for this study was taken from existing clinical notes.  No quality of life 
outcome data are available for the patient group.  This limited outcome calculation 
to viral load suppression which, while a good indicator of clinical improvement on 
ART, does not reflect many of the patient level concerns and a broader outcome.   
Because of the higher costs associated with TDF based regimens and the 
limited resources in developing countries, long term studies of TDF in developing 
countries are not available.  The utilization data was therefore limited to the 
substitution of data from the ‘remainder’ cohort for patients once they would be on 
TDF.  Outcome data was limited in a similar manner.  In sensitivity analysis, data on 
outcomes on TDF in comparison to d4T and AZT were sourced from studies in the 
developed world.  Patient level and health system constraints in the developing 
world could effect the utilization and outcome results for TDF in these settings.   
As this study took a health system perspective, costs associated with a 
societal perspective have been excluded.  These costs include the added costs of 
d4T or AZT regimens over TDF regimens on the patient, family, and society.  
Discomfort from side effects could lead to lower productivity in the home and 
workplace.  More frequent medical appointments would lead to greater travelling 
expenses and time off from work or family obligations for the patient and perhaps a 
supporter.  Death of the patient due to side effects could reduce household income 
in the case of an employed patient.  It could also lead to weakened family ties and a 











  While this study based utilization of health services for patients on TDF on a 
‘remainder’ cohort of patients and used viral load suppression as an outcome, a 
recent study modelled utilization of health services, rates of side effects, and 
QALYs gained on TDF in a South African setting (Rosen, et al., 2008).  The study 
addressed the cost and cost-effectiveness of switching from a d4T based first line 
regimen to a TDF regimen for all patients starting on ART.  Data from published 
reports and clinicians’ experience were used to estimate parameters for TDF 
utilization.  The allocation of weights and duration for loss of QALYs per event were 
assigned from literature or estimated by clinical experience.  Using these data, 
patients on TDF regimens had fewer events requiring change of regimen, and far 
fewer QALYs lost in comparison to the d4T patients.  Despite the discrepancy in 
side effects and drug changes between the TDF and d4T groups, the high cost of 
TDF offsets added clinical and management costs.  However, due to the benefits of 
TDF, a TDF first line regimen would be cost-effective at a price slightly lower than 
the current price. However in this case cost-effectiveness was based on a 
comparing the ICER to the GDP per capita which can be disputed.  It would take a 
significant decrease in cost in order to make a full TDF first line regimen cost-
neutral.   
The alternative methods for determining costs and outcome in the above 
study and the results they yield, in combination with the alternative TDF 
implementation models discussed in this GF Jooste Hospital study, motivate for 
further research as to how TDF could be integrated into the South African first line 











Chapter 6: Conclusion and Policy Implications 
This study has shown that two options for the implementation of TDF as a 
first line ART lead to higher costs than currently incurred under the status quo.  
Data from the GF Jooste patient group has indicated that the higher costs 
associated with TDF would not result in significantly improved outcomes if this is 
measured narrowly as percent virally suppressed at 18 months. However, other 
benefits of TDF such as decreased frequency of side effects, lower pill burden, and 
ease of health management should not be discounted when making this decision.  
Sensitivity analysis with outcome data from the developed world yields 
ICERs of R114.26 and R96.68 per percentage of patients virally suppressed over 
18 months for arm 2 over the status quo.  The data results in ICERs of R456.77 and 
R153.24 per percent of patients virally suppressed over 18 months for arm 3 over 
arm 2.   
Threshold analysis indicates that a reduction to 83.5% of the current TDF 
price would make arm 2 cost neutral.  While the outcome of increased viral 
suppression is not significantly different in the GF Jooste cohort or in published 
comparisons to d4T (Gallant, et al., 2004), these outcomes do not capture the 
broader patient based concerns that QALYs would.  In addition, the societal costs 
associated with side effects from d4T and AZT have not been included.  The 
potential added costs and benefits, some of which are indicated in a recent study 
(Rosen, et al., 2008), of a TDF regimen warrant investigation.  If TDF were to be 
introduced as a first line regimen, the most cost effective option would be to change 
patients to TDF once they develop side effects.   
If budgets cannot be increased, implementing a TDF based first line ART 
regimen would imply less access to HIV care for those in need while having little or 
no improvement in viralogical outcomes for patients.  Morbidity and mortality 
including quality of life improvements and the positive impact that they may have on 
adherence and treatment success have not been reflected in this study.  While TDF 
should not be introduced into first line ART at present, there are reasons to 
consider its future inclusion.  As TDF reduces the burden on patient management, 
doctors’ and nurses’ time can be allocated to increasing the number of patients on 
ART.  As human resources are likely the critical constraint in the public health care 
system, an intervention that leads to a better use of the available resources could 
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Utilization of health resources by cohort (cost per patient in SA Rands Sept 2008)








ID appointment 1098.92 1067.01 1192.80 1125.36 1093.31 1130.49
IDR appointment 243.95 192.28 278.88 361.41 219.04 65.17
Ward day 19.58 28.16 73.49 0.00 23.74 0.00
ART regimen 457.30 469.49 460.46 495.32 464.94 494.23
Laboratory Investigations 303.28 297.57 316.31 312.84 301.25 277.68
Total quarter 1 2123.03 2054.52 2321.93 2294.92 2102.28 1967.58
Quarter 2 
ID appointment 601.13 586.40 637.66 591.49 603.15 572.80
IDR appointment 87.90 81.32 71.20 0.00 106.34 0.00
Ward day 6.19 27.98 18.37 0.00 7.48 0.00
ART regimen 466.44 511.55 463.77 477.73 489.82 478.50
Laboratory Investigations 382.36 376.19 394.51 341.95 390.84 336.92
Total quarter 2 1544.02 1583.43 1585.52 1411.17 1597.62 1388.23
Quarter 3 
ID appointment 510.87 499.89 532.10 532.19 507.95 529.69
IDR appointment 18.35 27.84 0.00 11.69 19.82 15.29
Ward day 6.31 9.58 0.00 0.00 7.67 0.00
ART regimen 459.69 486.56 414.26 473.32 471.34 477.79
Laboratory Investigations 100.28 92.70 114.93 99.97 100.66 81.14
Total quarter 3 1095.51 1116.58 1061.29 1117.18 1107.43 1103.91
Quarter 4 
ID appointment 571.30 516.19 683.27 498.12 586.71 484.89











Ward day 28.78 9.77 18.51 165.35 0.00 0.00
ART regimen 488.36 512.39 442.83 472.69 491.66 482.17
Laboratory Investigations 348.12 298.24 442.64 296.52 358.99 274.76
Total quarter 4 1484.05 1364.98 1641.05 1527.63 1474.87 1304.18
Quarter 5 
ID appointment 516.06 457.76 622.95 536.13 511.76 514.69
IDR appointment 27.64 19.71 42.16 0.00 33.56 0.00
Ward day 6.58 5.09 18.65 0.00 7.99 0.00
ART regimen 533.55 539.52 522.63 527.52 534.85 506.50
Laboratory Investigations 170.25 123.78 256.44 118.39 181.37 96.87
Total quarter 5 1254.09 1145.86 1462.83 1182.04 1269.53 1118.06
Quarter 6 
ID appointment 479.05 442.81 547.04 463.96 482.26 426.23
IDR appointment 8.57 13.14 0.00 48.93 0.00 63.61
Ward day 3.32 5.09 0.00 18.94 0.00 24.62
ART regimen 548.06 544.14 564.56 525.69 556.67 506.50
Laboratory Investigations 317.77 279.38 380.42 309.97 319.43 298.97
Total quarter 6 1356.77 1284.56 1492.03 1367.49 1358.35 1319.93
18 month total 8857.47 8549.92 9564.66 8900.43 8910.10 8201.89
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